European biotech financing gravitates to Benelux
This article was originally published in Scrip
Executive Summary
European entrepreneurs looking to establish new biotech companies are more likely to raise the funds they need by looking to the Benelux rather than the traditional powerhouses of the UK and Germany. Dr Edwin Moses, chief executive officer and chairman of Ablynx, the Ghent-based camelid antibody company and a serial entrepreneur, doubts whether start-ups can raise the hundreds of millions of Euros necessary to discover and develop new medicines in any market other than those emerging in the Benelux countries.